GlassScriptPhysician profile
Priyanka Chugh
NPI 1700147915
$9,961.12
in general payments reported to CMS, 2019-2025
33 companies · $3,994 in 2025
The $3,994 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.19 · 2020: $21.04 · 2022: $236 · 2023: $2,132 · 2024: $3,480 · 2025: $3,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,577 · Education: $28.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,577.09 |
| Education | $28.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.11 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,225.50 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,131.38 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $999.19 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $668.65 | 2023-2025 | |
| Genzyme Corporation | $583.69 | 2023-2025 | |
| Ardelyx, INC. | $477.20 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $467.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $423.46 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $357.78 | 2023-2025 | Sucraid, Sucraid |
| Exact Sciences Corporation | $304.14 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $294.11 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $240.37 | 2023-2025 | Ocaliva |
| Celgene Corporation | $222.90 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $190.42 | 2023-2025 | Dupixent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $181.04 | 2023-2024 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $150.36 | 2024-2025 | Iqirvo |
| Boston Scientific Corporation | $121.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.34 | 2022 | |
| Ironwood Pharmaceuticals, INC | $83.21 | 2023-2024 | Linzess |
| Gilead Sciences, INC. | $73.44 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $59.02 | 2025 | Zenpep |
| Redhill Biopharma INC. | $47.25 | 2023-2024 | Talicia, Aemcolo |
| Evoke Pharma, INC. | $44.53 | 2024 | |
| Intra-Sana Laboratories | $40.78 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Braintree Laboratories, INC. | $29.99 | 2024-2025 | Sutab, Suflave |
| Celltrion USA INC. | $28.35 | 2024 | Zymfentra |
| Amgen INC. | $27.77 | 2023 | Amjevita, Avsola |
| Organon LLC | $26.77 | 2025 | Hadlima |
| Biocon Biologics INC | $26.34 | 2025 | Yesintek |
| Nestle Healthcare Nutrition INC. | $25.05 | 2023 | |
| Merck Sharp & Dohme LLC | $13.95 | 2024 | Dificid |
| Micro-Tech Endoscopy USA, INC. | $11.42 | 2023 | Lesion Hunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyanka Chugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.